PTSD: cannabis research overview
Care should focus on treatments suited to PTSD, particularly evidence-based trauma-focused psychotherapy. Sleep, re-experiencing, avoidance and heightened arousal need separate assessment. People already using cannabis should be able to discuss it without shame. An appointment can clarify which symptoms are being targeted and which might relate to use or changes in use.
Research profile, not a treatment recommendation
Evidence
Available studies do not support a reliable general recommendation. Observed improvements can have several causes and are not automatically a demonstrated medicine effect. A plausible mechanism involving REM sleep is not a substitute for clinical evidence. A blanket claim that cannabis prevents long-term emotional processing would also overstate what is known. For each study, check who participated, what was compared and whether the measured difference matters in everyday life.
Mechanism of action
A mechanism described in a laboratory is not evidence of benefit in humans. Clinical outcomes for the specific condition and medicine matter. Receptor or terpene models do not predict individual treatment success.
Understanding cannabinoid and terpene profiles
The diagnosis alone cannot establish a universally recommended THC:CBD ratio or terpene profile. Pharmaceutical quality, the studied use and personal risks matter. A strain name or aroma profile cannot replace that assessment.
Individual dosing and monitoring
This reference provides no starting dose or escalation schedule. If treatment is considered, the preparation, dose, adjustments and monitoring must be individualised. Different products are not directly interchangeable; drops and sprays are not universal dose units.
Routes of administration
The route of administration is part of choosing a specific medicine. Results for one standardised preparation do not automatically establish the effects of another form. Discuss changes with the treating clinician.
Side effects
THC can worsen anxiety, panic or suspiciousness in some people. Describe immediate relief alongside effects on daily life, concentration and treatment. Problematic use calls for support, not leaving PTSD untreated. An acute mental health crisis or immediate danger to yourself requires urgent help; in Switzerland call 144 or 112.
Interactions & cautions
Have the complete medication list checked, including non-prescription products. CBD can also cause interactions. Pregnancy, breastfeeding, liver disease and previous mental health difficulties may matter; the specific medicine’s prescribing information is decisive.
Prescription & insurance (Switzerland)
Since August 2022, medical prescribing of cannabis medicines no longer requires an exceptional FOPH permit. This does not establish authorisation for every condition or automatic reimbursement. The preparation, indication and applicable reimbursement rules need separate assessment.
Driving fitness
If a person can demonstrate that THC comes from medication prescribed by a doctor, its presence alone does not establish unfitness to drive (Article 2(2ter) of the Swiss Traffic Rules Ordinance). Actual driving ability remains decisive. A prescription is therefore not blanket permission to drive. Discuss possible effects on attention and reactions with your treating clinician. Do not drive while impaired, and take particular care when starting or changing treatment. Safety-sensitive tasks at work also need an individual assessment.
FAQ
What can be said about effectiveness?
Cannabis is not an established treatment for post-traumatic stress disorder. The US VA/DoD guideline from 2023 recommends against it because of insufficient efficacy evidence and risks. This is an international clinical position, not Swiss law. Individual reports of better sleep or fewer nightmares do not establish treatment of PTSD as a whole.
Does a prescription guarantee reimbursement?
No. Prescribing, medicine authorisation and reimbursement are separate questions. Clarify which rules apply to the preparation and indication, including whether prior reimbursement approval is needed.
Is there a universally recommended product profile?
The diagnosis alone cannot establish a universally recommended THC:CBD ratio or terpene profile. Pharmaceutical quality, the studied use and personal risks matter. A strain name or aroma profile cannot replace that assessment.
Does a prescription automatically allow driving?
A prescription alone cannot answer that question. Where medically prescribed use is demonstrated, detecting THC does not by itself establish unfitness to drive. Driving while impaired remains prohibited. Discuss your individual circumstances with your treating clinician.